FDA Schedules Advisory Panel To Review Neovasc’s Angina Treatment

The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.

MT2007_FDA Advisory Comm_292512269_1200.jpg
• Source: shutterstock.com

More from Clinical Trials

More from R&D